ArticlePloS one2026
Design and evaluation of a novel fusion antigen for diagnosing human strongyloidiasis: An immunoinformatics approach.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Strongyloidiasis, caused by Strongyloides stercoralis, remains a neglected tropical disease (NTD) with significant clinical implications, particularly in immunocompromised individuals. Current serological assays for diagnosing strongyloidiasis are limited by suboptimal sensitivity and specificity. The development of recombinant fusion proteins for serodiagnostic applications represents a promising strategy to improve diagnostic accuracy. This study aimed to design a novel recombinant fusion antigen for the serodiagnosis of strongyloidiasis, using immunoinformatics approaches. Four immunogenic proteins (SsIR, L3NieAg.01, Ss3a, and Ss1a) were selected for the design of the fusion antigen. The most immunogenic regions of these proteins were identified based on epitope density and minimal cross-reactivity, and they were linked, using EAAAK linkers. The designed fusion antigen was then evaluated for its physicochemical properties, solubility, antigenicity, and potential cross-reactivity. Its three-dimensional (3D) structure was predicted, and the nucleotide sequence was codon-optimized to ensure efficient expression in Escherichia coli (E. coli). Finally, the optimized sequence was in silico cloned into the pET23a(+) expression vector. Immunoinformatics analyses demonstrated that the designed fusion antigen exhibits appropriate stability and robust antigenicity while showing no significant cross-reactivity. Codon optimization resulted in a codon adaptation index (CAI) of 0.92, and a GC content adjusted to 47%, confirming its compatibility with the E. coli expression system. Furthermore, no inhibitory cis-regulatory elements or repetitive sequences were identified post-optimization, supporting the feasibility of successful recombinant expression in E. coli. The bioinformatics findings of this study indicate that the designed fusion antigen holds significant potential for incorporation into ELISA-based serodiagnostic assays for strongyloidiasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.